April 24 (Reuters) - Qyuns Therapeutics Co Ltd 2509.HK:
ENTERS EXCLUSIVE LICENSE AGREEMENT WITH CALDERA THERAPEUTICS
CALDERA THERAPEUTICS GRANTED EXCLUSIVE RIGHTS TO QX030N
TO RECEIVE $10 MILLION UPFRONT PAYMENT AND 24.88% EQUITY IN CALDERA
Further company coverage: 2509.HK
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.